Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer

Cisplatin resistance remains a major problem in the treatment of lung cancer. We have discovered that cisplatin resistant (CR) lung cancer cells, regardless of the signaling pathway status, share the common parameter which is an increase in reactive oxygen species (ROS) and undergo metabolic reprogr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wangpaichitr, Medhi, Wu, Chunjing, Li, Ying Ying, Nguyen, Dan J.M., Kandemir, Hande, Shah, Sumedh, Chen, Shumei, Feun, Lynn G., Prince, Jeffrey S., Kuo, Macus T., Savaraj, Niramol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564767/
https://www.ncbi.nlm.nih.gov/pubmed/28525376
http://dx.doi.org/10.18632/oncotarget.17568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564767/
https://www.ncbi.nlm.nih.gov/pubmed/28525376
http://dx.doi.org/10.18632/oncotarget.17568

Ejemplares similares